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in pregnancy: systematic review and meta-analysis
R. Matthew Chico1, Jorge Cano1, Cono Ariti1,2, Timothy J. Collier1, Daniel Chandramohan1, Cally Roper1 and
Brian Greenwood1
1 London School of Hygiene & Tropical Medicine, London, UK
2 Nuffield Trust, London, UK
Abstract objectives To estimate where intermittent preventive treatment (IPTp) using sulphadoxine–
pyrimethamine (SP) could be withdrawn as an intervention due to declining malaria transmission
intensity, or due to increasing prevalence of the Plasmodium falciparum dihydropteroate synthetase
resistance mutation at codon 581G.
methods We conducted a systematic review and meta-analysis of protection against the incidence
of low birth weight (LBW) conferred by ≥2 doses of IPTp-SP. We matched these outcomes to a proxy
measure of malaria incidence in women of the same studies, applied meta-regression models to these
data and conducted sensitivity analysis of the 581G mutation.
results Variation in the protective effect of IPTp-SP against LBW could not be explained by
malaria transmission intensity. Among primi- and secundigravidae, IPTp-SP protected against LBW
where 581G was ≤10.1% [odds ratio (OR): 0.49; 95% confidence intervals (CI): 0.29, 0.81;
P = <0.01] and 581G was >10.1% (OR = 0.73; 95% CI: 0.29, 1.81; P = 0.03). Random-effects
models among multigravidae showed that IPTp-SP protects against LBW where 581G was ≤10.1%
(OR = 0.56; 95% CI: 0.37, 0.86; P = 0.07), a finding of borderline statistical significance. No
evidence of protection against LBW was observed where 581G was >10.1% (OR = 0.96; 95% CI:
0.70, 1.34; P = 0.47).
conclusion There appears to be a prevalence of 581G above which IPTp-SP no longer protects
against LBW. Pregnancy studies are urgently needed where 581G is >10.1% to define the specific
prevalence threshold where new strategies should be deployed.
keywords malaria , pregnancy, sulphadoxine–pyrimethamine, drug resistance, transmission,
sub-Saharan
Introduction
The World Health Organization (WHO) recommends the
provision of intermittent preventive treatment (IPTp) using
sulphadoxine–pyrimethamine (SP) at every scheduled ante-
natal care visit, from the second trimester until delivery, in
areas of moderate (stable) to high transmission to protect
pregnant women against the adverse consequences of
malaria infection. Although sulphadoxine and pyrimetha-
mine are synergistic and produce complimentary inhibi-
tion, several mutations are associated with decreased
parasite sensitivity. Parasite resistance to SP is associated
with mutation on the dihydrofolate reductase (Pfdhfr) and
the dihydropteroate synthetase (Pfdhps) genes. Three Pfd-
hfr mutations, namely N51I, C59R and S108N, are com-
monly referred to as the triple mutation; Pfdhps mutations
A437G and G540E are often described as the double
mutation. Collectively, these constitute the quintuple
mutations and compromise SP efficacy [1–3]. The effec-
tiveness of IPTp-SP to prevent low birth weight (LBW)
decreases with increasing population prevalence of Pfdhps
K540E mutation – a proxy for the quintuple Pfdhfr and
Pfdhps mutant – although some beneficial effect on birth
The copyright line for this article was changed on 20 October
2015 after original online publication.
© 2015 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 1
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Tropical Medicine and International Health doi:10.1111/tmi.12595
volume 00 no 00
weight remains evident in areas where Pfdhps K540E is
even above 90% [4]. Importantly, however, IPTp-SP fails
to inhibit parasite growth where the Pfdhps A581G muta-
tion has emerged alongside the Pfdhfr and Pfdhps quintu-
ple mutant to produce ‘sextuple’ mutant parasites [5].
Thus, the population prevalence of 581G has assumed a
central role in IPTp-SP policy discussions [6].
With historic reductions in malaria transmission
observed in some countries of sub-Saharan Africa over
the past decade and increasing parasite resistance to SP
during the same time period, two questions have come to
the forefront related to IPTp-SP. Is there a level of
malaria transmission intensity below which IPTp-SP no
longer prevents LBW at the population level and can be
withdrawn? Secondly, is there a prevalence threshold of
581G which renders falciparum parasites ‘super resistant’
to SP and above which IPTp-SP is no longer protective
against LBW and can be withdrawn?
To answer these questions, we delineated three objec-
tives for this study. The first objective was to conduct a
systematic review and meta-analysis of IPTp-SP studies
that have reported the protective effect against LBW by
gravidae. The second objective was to use meta-regression
analysis to determine whether there was a level of malaria
transmission intensity below which IPTp-SP no longer
conferred protection against LBW at the population level.
The third objective was to use sensitivity analysis among
these same IPTp-SP studies to determine whether 581G
prevalence appeared to affect LBW outcomes.
These objectives could be achieved most directly with evi-
dence from new, large, placebo-controlled randomised clini-
cal trials conducted in endemic areas with narrowly
different levels of low transmission or resistance. However,
the use of placebo where IPTp-SP is policy, or the withhold-
ing of preventive treatment to create an unprotected com-
parison group, raises ethical concerns. Thus, analysis needs
to be conducted using available data. This has its own set of
challenges, particularly as it relates to our second objective.
Maternal parasitaemia is highest between gestational weeks
9 and 16, and then tapers until term [7], but IPTp-SP studies
almost exclusively measure parasitaemia only once, at or
near delivery, producing a point estimate that has been
influenced by the total amount of antimalarial drug adminis-
tered during the antenatal period and by near-to-term ther-
apy. Thus, antenatal exposure to malaria infection is often
understated in IPTp-SP studies. A proxy measure for
malaria transmission intensity is needed. This proxy should
lend itself to stratification by gravidae because malaria infec-
tion in endemic areas is known to be more prevalent and
intense in primi- and secundigravidae than among multi-
gravidae [7]. The proxy we chose is the prevalence of
malaria infection among children.
Methods
Systematic review
A systematic review of the literature on malaria in preg-
nancy was completed in August 2014. The protocol can
be found in the International Prospective Register of Sys-
tematic Reviews (PROSPERO; CRD42014007618). In
brief, we searched PubMed, MEDLINE, EMBASE, the
WHO International Clinical Trials Registry and reference
lists to identify pregnancy studies that reported: (i) the
proportion of pregnant women who were exposed to ≥2
doses of IPTp-SP compared to placebo, or to no doses of
IPTp-SP, and (ii) the incidence of LBW by treatment
group. We imported records into EndNote X7 software
(Thomson Reuters), removed duplicates and screened
each record against pre-determined eligibility criteria.
Discrepancies in eligibility assessment were settled by a
third-party expert. We reviewed full-text articles against
the same criteria. Studies were excluded if they were con-
ducted: (i) before 1990, (ii) outside sub-Saharan Africa,
(iii) without reporting the effect of IPTp-SP on LBW,
(iv) with selective enrolment of pregnant women from
high-risk groups such as those with HIV or (v) utilised
active antimalarial drug comparators against IPTp-SP.
Figure 1 illustrates our selection process, the number of
studies excluded and the reasons for their exclusion in
accordance with guidelines from the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA). Table S1 is the PRISMA checklist. We
extracted data without blinding to author or publication,
but we did so in duplicate and independently, and then
applied methods of Grading of Evidence, Assessment,
Development and Evaluation (GRADE) to appraise data
quality. RevMan 5.2 software was used to determine the
risk of bias among individual pregnancy studies and
across studies (Oxford, UK).
Meta-analysis
We conducted a standard meta-analysis employing Stata/
IC version 13 software (Stata Corporation) using the
results of our systematic review without regard for
malaria transmission intensity on LBW outcomes. We
pooled the incidence of LBW by gravidae and by expo-
sure to ≥2 doses of IPTp-SP vs. placebo or no doses, and
assessed our results with the Q statistic.
Estimating malaria transmission intensity
We employed two methods to estimate the malaria trans-
mission intensity that was likely to have been present in
each IPTp-SP study site. Our first approach was to use
2 © 2015 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
Tropical Medicine and International Health volume 00 no 00
R. M. Chico et al. IPTp: Transmission intensity & 581G mutation
the 2007 prevalence estimates of Plasmodium falciparum
infection among children 2–10 years of age (2007
PfPR2–10) as calculated by the Malaria Atlas Project
(MAP) for the same locations where IPTp-SP studies had
been conducted. However, because all our IPTp-SP stud-
ies had been conducted prior to 2007, with the exception
of one multi-year trial that ended in 2007, we sought
prevalence estimates that better aligned with the years of
the pregnancy studies. For this, we obtained national
cross-sectional survey data sets from MAP of P. falci-
parum prevalence for each of the 12 countries where the
IPTp-SP studies had been conducted. We then developed
four matching rules shown in Table 1 to identify point
estimates from the cross-sectional data that were most
likely to reflect the malaria transmission intensity to
which pregnant women were exposed.
Before applying these matching rules, we extracted
geospatial coordinates for each IPTp-SP study and cross-
sectional survey using the GEOnet Names Server [8]
and then used ArcGIS 10 software (Environmental Sys-
tems Research Institute) to calculate straight-line dis-
tances between the locations of IPTp-SP studies and
cross-sectional surveys. This allowed us to restrict
matching of IPTp-SP studies to survey data that had
been collected within <100 miles of each other as
described in rule 1, a distance used in previous malaria
modelling of pregnancy and paediatric data [9]. Simi-
larly, we obtained elevation estimates from the Consor-
tium for Spatial Information [10] for locations of the
IPTp-SP studies and survey data. We used these esti-
mates as part of an elevation criterion in rule 3 that
took into account the fact that malaria infection decli-
nes sharply at altitudes ≥1200 m compared to lower ele-
vations [11]. We also included a temporal criterion in
the matching rules, stipulating that survey data needed
to have been collected within 2 years of the IPTp-SP
studies to be paired. All four matching rules required
that cross-sectional surveys and pregnancy studies had
to have been conducted in areas from the same malaria
transmission category as designated by MAP: high
(>40% P. falciparum prevalence among 2–10 year olds),
intermediate (5–40%) and low (<5%). This accounted
for the possibility that IPTp-SP studies and cross-sec-
tional surveys may have been conducted in proximate
locations that had very different intensities of malaria
transmission. To reflect the gravidae-specific nature of
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parasitaemia among pregnant women in endemic areas
when pairing prevalence estimates of malaria in chil-
dren, we made some assumptions based on reports from
Sierra Leone [12] and Kenya [13] that suggest the
prevalence of parasitaemia among children is compara-
ble to maternal parasitaemia as presented in Table 2.
We then applied our matching rules sequentially. If
survey data could not be matched to an IPTp-SP study
using rule 1, then rule 2 was applied, and so on until
we identified all point prevalence estimates from survey
data that could be considered the best possible matches
for each IPTp-SP study as illustrated in Figure 2. Using
random-effects models, we pooled survey data that were
paired with IPTp-SP studies under rules 1, 2 or 3. If
survey data could not be matched under these rules, we
imposed the 2007 PfPR2–10 estimate for the same loca-
tion where the IPTp-SP study had been conducted.
Meta-regression analysis
With data from IPTp-SP studies paired to malaria preva-
lence estimates, whether using 2007 PfPR2–10 or our
pooled estimates, we applied standard meta-regression
models [14, 15] to LBW outcomes reported in the IPTp-
SP studies. This allowed us to correct for the variances of
treatment effect within pregnancy studies, and the resid-
ual heterogeneity across pregnancy studies, and to esti-
mate the effect of malaria transmission intensity on the
protection conferred by IPTp-SP against LBW.
Potential effect modification of Pfdhps 581G on
outcomes
Because the Pfdhps 581G mutation may have acted as an
important effect modifier, we used the geographical data-
base of molecular biomarkers as described elsewhere [16]
to obtain point prevalence estimates of the 581G muta-
tion associated with ‘super resistance’ to SP among para-
sites from the same locations where IPTp-SP studies had
been conducted. We included mutation prevalence esti-
mates if they had been collected from <100 miles of the
Table 1 Rules used to match low birth weight outcomes in
IPTp-SP studies with point estimates from prevalence surveys of
Plasmodium falciparum infection among children
Rules Criteria
1 Prevalence estimates will be paired to IPTp-SP studies
if they were both conducted:
In an area with the same risk of malaria infection
(high, intermediate or low), AND
Within 2 years (+ or ) of each other, AND
<100 miles of each other
2 Prevalence estimates will be paired to IPTp-SP studies
if they were both conducted:
In an area with the same risk of malaria infection
(high, intermediate or low), AND
Within two years (+ or ) of the pregnancy study, AND
In the same country
3 Prevalence estimates will be paired to IPTp-SP studies
if they were both conducted:
In an area with the same risk of malaria infection
(high, intermediate or low), AND
At the same elevation, either ≤1200 m OR >1201 m,
AND
In the same subregion of Africa (East/Southern OR
West/Central)
4 If no prevalence estimates can be paired, then IPTp-SP
studies will be matched to the 2007 PfPR2–10 estimate
Table 2 Age structure of paediatric data matched to gravidity
Paediatric description Age structure Gravidity
Infancy Birth to <1 Primigravidae
Childhood 1–4 Segundigravidae
School-aged 5–15 Multigravidae
Multigravidae
Rule 1: 4 studies matched
Rule 2: 0 studies matched
Rule 3: 2 studies matched
Rule 4: 2 studies matched
Primi- and secundigravidae: reported by 12 study sites
Multigravidae: reported by 10 study sites
9 pregnancy studies
11 548 point prevalence estimates from
MAP database applied to matching rules
Primi- and secundigravidae
Rule 1: 6 studies matched
Rule 2: 0 studies matched
Rule 3: 5 studies matched
Rule 4: 1 study matched
Figure 2 Flow diagram that illustrates
the pairing of pregnancy studies to
paediatric malaria prevalence estimates.
4 © 2015 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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IPTp-SP studies and within 2 years of when the IPTp-
SP studies had been conducted. This radius was expanded
to 100–250 miles if no data were available from <100
miles. If multiple point estimates were found, we pooled
them using standard meta-analysis. We then conducted a
sensitivity analysis of the 581G mutation on our results.
Results
Systematic review
Studies of IPTp-SP stratified by gravidae that met inclu-
sion criteria are summarised in Table 3 [17–25]. Nine
studies involving 10 279 pregnant women were included
in our analysis. Seven studies reported LBW outcomes
from 12 unique sites for primi- and secundigravidae who
were exposed to ≥2 doses of IPTp-SP (N = 2314) vs. pla-
cebo or no doses (N = 1954). In addition, seven studies
from 10 unique sites reported LBW outcomes among
multigravidae who received ≥2 doses of IPTp-SP
(N = 2941) compared to placebo or no doses
(N = 3070).
Funnel-plot analysis in Figure S1 suggests that rela-
tively small IPTp-SP studies failing to protect against
LBW may have been under-represented in our sample.
Our appraisal of evidence using GRADE methods is sum-
marised in Table S2. Figure S2 illustrates the risk of bias
within individual IPTp-SP studies, and Figure S3 shows
the combined risk of bias across IPTp-SP studies. Five of
the nine studies were randomised clinical trials, whereas
four were observational studies. There is an unclear risk
of selection bias and detection bias in one-half of the
studies.
Meta-analysis
Random-effects models produced statistically strong evi-
dence among pregnancy studies; among primi- and
Table 4 Pooled prevalence estimates and Malaria Atlas Project (MAP) estimates at study sites by primi- and secundigravidae and
multigravidae
References Countries Sites Elevation Matching rule used Pooled prevalence (%) 2007 PfPR2–10 (%)
Primi- and secundigravidae
Likwela [17] DR Congo Rutshuru 1212 4 29.6* 29.6
Ndyomugyenyi [18]† Uganda Kabale 2118 4 29.6* 25.1
Ndyomugyenyi [18]‡ Uganda Kabale 2118 4 29.6* 25.1
Likwela [17] DR Congo Kisangani 401 1 30.4 40.2
Menendez [19] Mozambique Manhica 21 1 31.2 48.1
Gies [20] Burkina Faso Boromo 258 1 44.2 57.4
Likwela [17] DR Congo Mikalayi 618 3 55.8 38.5
Ramharter [21] Gabon Libreville 13 3 55.8 37.1
Ramharter [21] Gabon Lambarene 39 3 55.8 42.8
van Eijk [22] Kenya Kisumu 1166 1 57.5 20.5
Sirima [23]† Burkina Faso Koupela 290 1 59.1 66.4
Sirima [23]‡ Burkina Faso Koupela 290 1 59.1 66.4
Multigravidae
Ndyomugyenyi [18]§ Uganda Kabale 2118 3 6.7 25.1
Ndyomugyenyi [18]¶ Uganda Kabale 2118 3 6.7 25.1
Mbaye [24] The Gambia Farafenni 25 1 8.3 23.9
Rogerson [25] Malawi Blantyre 989 3 11.3 24.9
Menendez [19]k Mozambique Manhica 21 3 11.3 48.1
van Eijk [22] Kenya Kisumu 1166 1 25.0 20.5
Likwela [17] DR Congo Rutshuru 1212 4 29.6* 29.6
Sirima [23] Burkina Faso Koupela 290 1 32.9 66.4
Likwela [17] DR Congo Kisangani 401 3 34.0 40.2
Likwela [17] DR Congo Mikalayi 618 1 39.3 38.5
Studies are presented in ascending order of malaria transmission intensity.
*Under rules 1–3, no matches were made and, therefore, the 2007 PfPR2–10 estimates from MAP are used.
†Primigravidae.
‡Secundigravidae.
§2–4 pregnancies.
¶5 or more pregnancies.
k1–3 pregnancies (likely contained some secundigravidae) and 4 or more pregnancies.
6 © 2015 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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secundigravidae, ≥2 doses of IPTp-SP vs. placebo or no
IPTp-SP reduced the odds of delivering a LBW newborn
by one-half [odds ratio (OR) = 0.54; 95% CI: 0.35, 0.84;
I2 = 69.0%; P < 0.00]. The reduction was 30% among
multigravidae (OR = 0.70; 95% CI: 0.51, 0.95;
I2 = 48.9%; P = 0.04). To explore whether heterogeneity
could be reduced, we stratified LBW outcomes as
reported in observational studies vs. RCTs. We found less
heterogeneity among the observational studies
(I2 = 34.7%; P = 0.190) than among RCTs (I2 = 76.5%;
P < 0.000) for primi- and secundigravidae. In contrast,
there was less heterogeneity in RCTs among studies in
multigravidae (I2 = 38.8%; P = 0.133) compared to
observational studies (I2 = 63.7%; P = 0.064).
Estimating malaria transmission intensity
We used 12 national cross-sectional data sets from MAP
containing 11 548 surveys to estimate the malaria trans-
mission intensity at each IPTp-SP study site. Table 4
shows the matching rules that we used and our pooled
prevalence estimates of malaria parasitaemia. Among
primi- and secundigravidae, the pooled prevalence ranged
between 25.1% and 59.1%, whereas MAP estimates
were between 20.5% and 66.4%. Among multigravidae,
pooled prevalence estimates ranged from 6.7% to 39.3%,
in contrast to MAP estimates which were between 20.5%
and 66.4%.
Meta-regression analysis
To explore the potential effect of malaria transmission
intensity on the association between IPTp-SP and LBW,
we produced four separate meta-regression models. In
Model 1, we used our pooled prevalence estimates among
primi- and secundigravidae for the measure of malaria
transmission intensity. In our second model, also for
primi- and secundigravidae, we applied MAP estimates
for malaria transmission intensity. In Models 3 and 4 for
multigravidae, we used our pooled prevalence estimates
and MAP estimates, respectively. None of the models
suggested that variation in the ORs of LBW could be
explained by malaria transmission intensity: Model 1
(P = 0.83), Model 2 (P = 0.78), Model 3 (P = 0.30) and
Model 4 (P = 0.93). Sensitivity testing among matching
rules did not produce any statistically significant differ-
ence.
Effect modification of Pfdhps 581G
Using a geographical database of molecular biomarkers
as described elsewhere [16], we obtained prevalence esti-
mates of Pfdhps 581G from 44 locations that had been
measured within 2 years of the IPTp-SP studies. There
were 20 locations within <100 miles of the pregnancy
study sites and 24 locations within 100–250 miles as
shown in Table 5 [26–40].
The highest prevalence estimates of 581G were calcu-
lated using data from four biomarker studies – Karema
[32], Alker [30], Lynch [31] and Taylor [29] – that
could be paired with two pregnancy studies – Likwela
et al. [17] and Ndyomugyenyi [18]. Specifically, these
four biomarker studies had 581G prevalence data from
six locations that were related to the Likwela [17]
pregnancy study (Rutshuru). We combined these point
estimates using random-effects models to produce a
pooled estimate of 52.4% [95% confidence intervals
(CI): 47.5–57.4%). We were able to relate five biomar-
ker studies that reported measurements of the 581G
mutation to the Ndyomugyenyi [18] pregnancy study.
We pooled these using random-effects models to gener-
ate an estimate of 52.6% (95% CI: 47.6–57.5%). The
biomarker study by Karema [32] that reported the pop-
ulation prevalence of 581G to be 61.1% also observed
dhfr-164L at a frequency of 11.4%. Similarly, popula-
tion prevalence estimates of 581G detected by Lynch
[31] were 45.8% (Rukungiri) and 45.0% (Kabale),
whereas lower frequencies, 4.2% and 13.7%, were
identified for 164L in the same locations, respectively.
The dhfr-164L mutation is also associated with the
failure of SP to clear malaria parasites and is more
commonly found in South American and South-East
Asia. Twelve biomarker studies reported the 581G
mutation that could be related spatially and temporally
to the remaining pregnancy studies. These prevalence
estimates ranged between 0.0% and 10.1% (95% CI:
3.5, 16.8). Overall, 581G prevalence points presented a
binomial structure – frequencies of 581G ≤10.1% and
those >10.1% – which we used to stratify IPTp-SP
studies.
Random-effects models shown in Figure 3 indicate that
≥2 doses of IPTp-SP reduced the odds of LBW among
primi- and secundigravidae (OR = 0.49; 95% CI: 0.29,
0.81; I2 = 67.7%; P < 0.00) and multigravidae
(OR = 0.56; 95% CI: 0.37, 0.86; I2 = 48.7%; P < 0.03)
in areas where the prevalence of 581G was ≤10.1%.
Where the prevalence of 581G was >10.1%, the protec-
tive effect of IPTp-SP persisted among primi- and
secundigravidae, although at lower levels, as illustrated in
Figure 4. Among multigravidae, random-effects models
showed that IPTp-SP confers protection against LBW in
areas where the prevalence of 581G was ≤10.1%
(OR = 0.56; 95% CI: 0.37, 0.86; P = 0.07), a finding of
borderline statistical significance. In contrast, there was
© 2015 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 7
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no evidence from fixed-effects or random-effects models
that multigravidae were protected against LBW at sites
where the prevalence of 581G was >10.1% (OR = 0.96;
95% CI: 0.70, 1.34; I2 = 72.0%; P < 0.47). The interac-
tion between malaria transmission intensity and the
prevalence of 581G was borderline significant: P = 0.06
among primi- and secundigravidae, and P = 0.04 among
multigravidae. Thus, meta-regression of malaria transmis-
sion intensity, stratified by the prevalence of 581G, was
only able to explain some of the variation in protective
effect of IPTp-SP against LBW.
Discussion
To our knowledge, this is the first use of age-stratified
rates of paediatric parasitaemia to model the gravidity-
specific relationship of malaria in pregnancy in endemic
settings, and our results conform to established epidemi-
ological patterns among pregnant women. In addition,
IPTp-SP studies identified through our systematic review
were protective against LBW to levels that are compara-
ble to other studies. We do not consider the age of the
data to be a limitation because we paired LBW out-
comes to parasite prevalence estimates from the same
time periods.
Lacking prevalence estimates for the 581G mutation
between 10.1% and 52.4%, we can only conclude that
the prevalence threshold of this mutation is >10.1%
above which IPTp-SP no longer protects against the inci-
dence of LBW. It is tempting to state the cut-off should
be >52.4%, but the threshold may be much lower, espe-
cially considering the alarming results from Tanzania
where placental infection was significantly higher in 84%
of women (n = 104) given any dose of IPTp-SP compared
to 16% of women (n = 104) who received none
(P = 0.03) [41, 42]. The prevalence of the 581G muta-
tion in this study area was 55% (95% CI: 44.7, 65.2;
N = 87) [43].
Study
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Gies (2009)
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Figure 3 Odds ratio of low birth weight delivery among primi- and secundigravidae following two or more doses of IPTp-SP vs.
placebo or no IPTp-SP stratified by estimates of the 581G resistance mutation among malaria parasites at study sites.
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Our results should be interpreted with caution. We
were limited by the relative paucity of data that relate
the efficacy of IPTp-SP to the intensity of malaria
exposure during pregnancy that has been stratified by
gravidae. Moreover, there may have been selection bias
in six of the nine studies we identified because of the
absence of random sequence generation or allocation
concealment. In addition, there was considerable hetero-
geneity among pregnancy studies. We are, however, hesi-
tant to draw any conclusions from stratifying studies by
design, and doing so did not consistently reduce hetero-
geneity.
We were unable to detect a malaria transmission
threshold below which IPTp-SP is no longer protective
against LBW, a possible consequence of there being too
few data points. However, an unpublished analysis of
Multiple Indicator Cluster Surveys also found that IPTp-
SP continued to protect against LBW until very low levels
of transmission and, similar to our analysis, could not
define a cut-off point of transmission below which
IPTp-SP is no longer protective against LBW (Eisele TP,
personal communication).
Our inability to detect a transmission threshold may be
due to other factors. We do not know the prevalence of
placental infection in very low-transmission settings and it
is entirely possible that declines in peripheral parasitaemia
are not reflected in equivalent reductions of placental
infection. If that is the case, then IPTp-SP may provide
important and continued protection against placental car-
riage and the incidence of LBW in areas of very low
endemicity. Another possible explanation is that the cau-
sal pathway to LBW is multifactorial and that IPTp-SP
offers some protection against other causes of LBW. SP
has been used as chemoprophylaxis against Toxoplasma
gondii infection and Pneumocystis carinii pneumonia
[44]. Sulphadoxine is related to sulphamethoxazole, the
partner compound used with trimethoprim to form co-tri-
moxazole which is commonly prescribed for urinary tract
infections [45]. Sulphonamide has also been used to treat
Gardnerella vaginalis [46], a bacterium found in women
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Figure 4 Odds ratio of low birth weight delivery among multigravidae following two or more doses of IPTp-SP vs. placebo or no
IPTp-SP stratified by estimates of the 581G resistance mutation among malaria parasites at study sites.
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with bacterial vaginosis which can double the odds of
having a LBW baby (OR = 2.0; 95% CI: 1.3, 2.9) com-
pared to pregnant women without bacterial vaginosis
[47]. A meta-analysis reported the prevalence of bacterial
vaginosis to be 50.8% (95% CI: 43.3, 58.4) among preg-
nant women attending antenatal care in East and South-
ern Africa and 37.6% (95% CI: 18.0, 57.2) in West and
Central Africa [48].
Additional insight could be gained from prospective
case–control studies that measure the incidence of LBW
among women who had received ≥2 doses of IPTp-SP vs.
women who had not to have received IPTp-SP during
their pregnancies. Such studies, however, can readily be
confounded.
Although the 581G mutation is not widely found
throughout sub-Saharan Africa, the codon has been
detected in 10 countries [49] and selection can be
alarmingly rapid. A study in Kenya reported the preva-
lence of 581G to be 85.1% (95% CI: 80.0%, 89.4%)
where no parasites had expressed the mutation 3 years
prior [50]. Before declaring a specific level of malaria
transmission or 581G prevalence at which IPTp-SP no
longer provides a cost-effective benefit, placebo-control
trials may be needed in a range of low-transmission
settings that have sufficient power for subanalysis by
gravidae and include robust micro-biological testing
that would enable exploration of potential protection
conferred by IPTp-SP against infections apart from
malaria. To our knowledge, there are no such studies
underway.
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